Foxo4 Dri: Research Applications

Aplicacoes de Pesquisa

FOXO4-DRI is utilized in preclinical research to study o efeitos of clearing celulas senescentes (senolysis) across 9+ research domains:

1. General Aging & Frailty — FOXO4-DRI restaura tissue homeostasis in naturally camundongos idosos (104–130 weeks). Benefits include melhorou fur density, aumentou physical activity (running wheel activity), melhorou responsiveness, and reduziu p16-driven bioluminescence (senescencia burden). Treatment of Xpd^TTD/TTD fast-aging mice yielded fur insulation restoration (approaching wildtype levels) and aumentou running from 1.37 km/day to near-wildtype levels.[1]
2. Chemotherapy-Induced Toxicity — In Doxorubicin-treated C57BL/6J mice, FOXO4-DRI (5 mg/kg i.v., 3 doses) neutralized chemotherapy-induziu liver toxicity (normalized plasma AST), preveniu peso corporal loss, and reduziu IL-6 and FOXO4 foci in liver tissue.[1]
3. Renal Function Decline — In ambos(as) fast-aging and naturally camundongos idosos, FOXO4-DRI normalizes plasma urea and creatinine levels, restoring kidney filtering capacity and reducing tubular senescencia markers. Significant reductions observado(a) 30 days after 3 i.p. injections.[1]
4. Male Hypogonadism / Testosterone Deficiency — In aged male mice (20–24 months), FOXO4-DRI selectively induz apoptose in senescent Leydig cells, reducing SASP factors (IL-1β, IL-6, TGF-β), improving the testicular microenvironment, and significantly restoring serum testosterone levels (p<0.05).[4]
5. Cardiovascular Aging & Endothelial Dysfunction — FOXO4-DRI reduz reactive oxygen species (ROS) no(a) aorta, suprime vascular aging markers (p16, p21), thins the aortic wall, lowers Pulse Wave Velocity (melhorou elasticity), and melhora endothelial-dependent vasodilatacao in ambos(as) naturally aged and D-galactose progeroid mice.[5]
6. Pulmonary Fibrosis — FOXO4-DRI melhora bleomycin-induziu pulmonar fibrose by targeting senescent myofibroblastos, downregulating matriz extracelular receptor interaction pathways, attenuating deposicao de colageno, and increasing Type 2 alveolar celula epitelials (AEC2).[8][9]
7. Osteoarthritis & Cartilage Regeneration — In expanded human condrocitos, FOXO4-DRI (25 µM, 5 days) selectively removed >50% of celulas senescentes (PDL9), reduziu SA-β-gal to <5%, and diminuiu expression of SASP factors (IL-6, IL-8) in engineered cartilage tissue.[6]
8. Cancer & Metastasis — FOXO4-DRI is being explored against therapy-resistant and metastatic cancers (triple-negative breast cancer, metastatic colon cancer) by targeting "scarred" cancer cells que share features with celulas senescentes, and for radiosensitizing non-small cell lung cancer.[10][11]
9. Liver Fibrosis — FOXO4-DRI and optimized variants (CL04183) counter the CD44-high dediferenciacao state in hepatocitos driven by senescencia, restoring liver function markers in fibrose models.[10]